Early divergence of treatment response trajectories to adalimumab or its biosimilar in active ankylosing spondylitis: consensus clustering analysis of a randomized controlled trial
BackgroundPatients with active ankylosing spondylitis (AS) exhibit substantial heterogeneity in their clinical responses to tumor necrosis factor alpha inhibitors (TNFi). Consensus clustering, an unsupervised cluster discovery method, may identify AS subgroups with more homogene…